<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CHOP) regimen in patients with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: HIV-seropositive patients with high-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>, or performance status less than 2 </plain></SENT>
<SENT sid="2" pm="."><plain>This multicenter phase II trial evaluated the response rate and disease-free survival after six courses of rituximab plus CHOP </plain></SENT>
<SENT sid="3" pm="."><plain>Results Sixty-one patients were enrolled </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the patients were assessable for safety and 52 were assessable for the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response after treatment completion </plain></SENT>
<SENT sid="5" pm="."><plain>Characteristics of patients were median age, 41 years; median CD4 cells, 172/microL; histology, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 42), <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> (n = 2), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27) </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3 or 4 toxicity consisted of febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in nine patients, <z:hpo ids='HP_0001903'>anemia</z:hpo> in 16 patients, and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in five patients </plain></SENT>
<SENT sid="7" pm="."><plain>Complete remission (CR) or unconfirmed CR was achieved in 40 of the 52 assessable patients, partial remission was achieved in five patients, and seven patients experienced progression </plain></SENT>
<SENT sid="8" pm="."><plain>Forty-three patients were alive after a median follow-up of 33 months </plain></SENT>
<SENT sid="9" pm="."><plain>The estimated 2-year overall survival rate was 75% (95% CI, 64% to 86%) </plain></SENT>
<SENT sid="10" pm="."><plain>Eighteen patients died: 16 as a result of <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, one as a result of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, and one as a result of <z:hpo ids='HP_0002383'>encephalitis</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, without increasing the risk of life-threatening <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
</text></document>